scientific symposium highlights optimisation of aerosol delivery in patients with poor asthma control aerosol delivery asthma

Optimisation of aerosol delivery in patients with poor asthma control

There is no excerpt because this is a protected post.

scientific symposium highlights optimisation of aerosol delivery in patients with poor asthma control aerosol delivery asthma

Optimisation of aerosol delivery in patients with poor asthma control

There is no excerpt because this is a protected post.

adjuvant hormonal therapy

Should all Women with Endocrine-Sensitive and Operable Breast Cancer Receive Adjuvant Hormonal Therapy?

One in six women with early, operable breast cancer may not need years of adjuvant hormonal therapy after primary treatment. This was the conclusion of a recent study published in JAMA (the Journal of the American Medical Association) Oncology.

2017 CICS immunooncology annual meeting oncology medical writer medipaper medical communications

Interested in Attending an Immunooncology Conference?

The CICS Annual Conference on Immuno Oncology is offering the most significant advances in the world of oncology. The goal of the meeting is to convey the clinical and translational advances in various areas of cancer immunology to medical oncologists, medical students, and other health professionals.

AMNOG Germany Pharmaceuticals Pricing Legislation MediPaper Medical Writer Hong Kong

AMNOG: Germany Pharmaceuticals Pricing Legislation Overview

Germany has introduced a new price-evaluation system for pharmaceuticals in 2011. How does this system work? And has the implementations been a successful one? An overview of the efficacy-measures of the AMNOG.

CIIO 2016 CICS immunooncology conference oncology medical writer medipaper medical communications

Interested in Attending an Immuno-Oncology Conference?

CIIO is an Annual Conference offering the most significant advances in the world of oncology. The goal of the meeting is to convey the clinical and translational advances in various areas of cancer immunology to medical oncologists, medical students, and other health professionals.

esmo 2016 breast cancer ribociclib palbociclib abemaciclib data medipaper medicall writer

ESMO16 Breast Cancer: Palbociclib, Ribociclib and Abemaciclib Data

Cyclin-dependent Kinase 4 and 6 (CDK4/6) inhibitors have shown clinical activity in patients with endocrine-resistant metastatic breast cancer. During the European Society for Medical Oncology (ESMO) Annual Meeting 2016, significant updates on studies with CDK4/6 inhibitors ribociclib, palbociclib and abemaciclib were presented.

PD-L1 Biomarker for Response DAKO 22C3 - MediPaper Medical Communications

PD-L1 Biomarker: a Comparison of ASCO2016 PD-1 and PD-L1 Data

There is no excerpt because this is a protected post.

Biomarkers Ipilimumab Treatment MediPaper Medical Communications

Novel Biomarker for Ipilimumab Treatment may aid Future Patient Selection in Several Malignancies

The number of different types of T-helper cells (Th) and cytotoxic T cells (CD8) may predict response to ipilimumab in several malignancies. This was concluded by Dr Juan Pablo Márquez Manríquez who presented the study at the ESMO conference on behalf of the investigators of the Sonora Cancer Research Center (CICS) in Mexico and the United States (U.S.).

ESMO 2016 ipilimumab data medipaper medical communications

ESMO16 Ipilimumab data – Download the PPT

There is no excerpt because this is a protected post.